Item 8.01 Other Events. On May 21, 2026, Cognition Therapeutics, Inc. (the “Company”) issued a press release announcing the completion of its meeting with the U.S. Food and Drug Administration for zervimesine in dementia with Lewy bodies patients with psychosis. A copy of the Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
CGTX Cognition Therapeutics Inc - 8-K
Accession
0001104659-26-0648638.019.01
Item 8.01 - Other Events
59 words
Item 9.01 - Financial Statements and Exhibits
37 words
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being furnished herewith: Exhibit No. Document 99.1 Press Release, dated May 21, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)